CSIMarket
 
Eupraxia Pharmaceuticals Inc   (NASDAQ: EPRX)
 

Eupraxia Pharmaceuticals Inc's Suppliers Performance

EPRX's Supply Chain




 
EPRX Costs vs Sales of Suppliers Growth

More on EPRX Suppliers






Eupraxia Pharmaceuticals Inc's Comment on Supply Chain


The company faces risks related to its suppliers and manufacturing of product candidates, including potential impacts if suppliers or licensees cease operations. Global geopolitical risks, such as the ongoing conflict between Russia and Ukraine, may affect clinical trial activities in Poland, the Czech Republic, and Denmark. Sanctions imposed by various countries on Russia, Ukraine, and Belarus could also adversely impact the company's operations. Additionally, the company is subject to anti-bribery and anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA), with potential penalties for violations. Recent changes in U.S. enforcement policy under the Trump administration may influence future enforcement actions, though the effects on the pharmaceutical industry and the company remain uncertain.

Eupraxia Pharmaceuticals Inc's Comment on Supply Chain


The company faces risks related to its suppliers and manufacturing of product candidates, including potential impacts if suppliers or licensees cease operations. Global geopolitical risks, such as the ongoing conflict between Russia and Ukraine, may affect clinical trial activities in Poland, the Czech Republic, and Denmark. Sanctions imposed by various countries on Russia, Ukraine, and Belarus could also adversely impact the company's operations. Additionally, the company is subject to anti-bribery and anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA), with potential penalties for violations. Recent changes in U.S. enforcement policy under the Trump administration may influence future enforcement actions, though the effects on the pharmaceutical industry and the company remain uncertain.







EPRX's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Eupraxia Pharmaceuticals Inc 320.45 0.00 -38.61 -
SUBTOTAL 0.00 0.00 0.00 -


Sources: Eupraxia Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Eupraxia Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.